Summit Therapeutics

Summit Therapeutics' stock climbed 5.8% in pre-market trading after Jefferies upgraded the stock from “Hold” to “Buy” and raised its price target from $15 to $25. Jefferies bases the recommendation on expected H3 data on progression-free survival to be reported at the end of 2026, which analyst Faisal Khurshid believes are likely to reach statistical significance provided the transfer of data from China shows no unusual deviations. The bank sees a probable hazard ratio of 0.65–0.70 for progression-free survival and expects a possible positive effect on overall survival by mid-2027; it also views the first-in-class status of ivonescimab as value-enhancing. » More on de.investing.com

New analyses show that Ivonescimab achieved a statistically significant benefit in overall survival versus Keytruda in Phase-III data. Partner Akeso successfully completed the HARMONi-2 study, reinforcing the potential of the lead compound. The results reduce development risk and strengthen the chances for future approvals and the company’s global market position. » More on finanzen.net

Summit Therapeutics shares rose about 4.8% premarket after partner Akeso released positive overall survival data from the Phase‑III HARMONi‑2 study of ivonescimab in non‑small cell lung cancer. The monotherapy showed a statistically significant advantage over pembrolizumab, but concrete metrics such as hazard ratio or median survival times were not disclosed. Ivonescimab is already approved and commercially available in China; in Summit’s licensed territories, including the USA and Europe, the drug is still under investigation. An analyst left the rating at neutral pending further details. » More on de.investing.com